Huntingdon, Harlan planning to rebrand; SynteractHCR focuses on oncology;

> After acquiring CRO Harlan Laboratories last year, Huntingdon Life Sciences is preparing to rebrand the combined company, which will split its operations between contract research and research models. News

> SynteractHCR has created the new position of vice president of strategic development, appointing CRO veteran Etienne Drouet to the post in an effort to boost its capacity in oncology and complex trials. Story

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.